open access

Vol 9, No 6 (2013)
Review paper
Published online: 2014-01-28
Get Citation

Postoperative therapy for uterine carcinoma. Overview of randomized trials

Krystyna Serkies, Ewa Pawłowska, Jacek Jassem
Onkol. Prak. Klin 2013;9(6):216-224.

open access

Vol 9, No 6 (2013)
REVIEW ARTICLES
Published online: 2014-01-28

Abstract

Uterine carcinoma, the most common gynaecological cancer, consists of different clinicopathological subtypes. This malignancy is usually diagnosed in early stages, is associated with low potential of both local recurrence and distant metastases, and its outcome is generally good. Surgery continues to be the cornerstone of therapy for tumours limited to the uterus. The optimal postoperative therapy — indications and forms, is still not determined. Postoperative radiotherapy was a subject of a few randomised trials, which demonstrated increased local control but no impact on overall survival. Higher rate of distant than local relapses in uterine carcinoma suggests potential role of systemic therapy in this malignancy. The benefit of postoperative endocrine or chemotherapy has not been confirmed in the randomised study. However, the most recently published, pooled results of two trials suggested prolongation of progression-free survival with the use of postoperative chemotherapy in addition to adjuvant radiotherapy in high-risk patients.

Abstract

Uterine carcinoma, the most common gynaecological cancer, consists of different clinicopathological subtypes. This malignancy is usually diagnosed in early stages, is associated with low potential of both local recurrence and distant metastases, and its outcome is generally good. Surgery continues to be the cornerstone of therapy for tumours limited to the uterus. The optimal postoperative therapy — indications and forms, is still not determined. Postoperative radiotherapy was a subject of a few randomised trials, which demonstrated increased local control but no impact on overall survival. Higher rate of distant than local relapses in uterine carcinoma suggests potential role of systemic therapy in this malignancy. The benefit of postoperative endocrine or chemotherapy has not been confirmed in the randomised study. However, the most recently published, pooled results of two trials suggested prolongation of progression-free survival with the use of postoperative chemotherapy in addition to adjuvant radiotherapy in high-risk patients.
Get Citation

Keywords

uterine carcinoma, radiotherapy, chemotherapy, endocrine therapy

About this article
Title

Postoperative therapy for uterine carcinoma. Overview of randomized trials

Journal

Oncology in Clinical Practice

Issue

Vol 9, No 6 (2013)

Article type

Review paper

Pages

216-224

Published online

2014-01-28

Bibliographic record

Onkol. Prak. Klin 2013;9(6):216-224.

Keywords

uterine carcinoma
radiotherapy
chemotherapy
endocrine therapy

Authors

Krystyna Serkies
Ewa Pawłowska
Jacek Jassem

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl